Overview of assigned therapy switches and discontinuations per treatment arm
| . | Ruxolitinib . | BAT . | Total . |
|---|---|---|---|
| Assigned therapy switches | |||
| Patients that switched BAT therapy at least once | N/A | 30 | 30 |
| Total number of times BAT therapy was switched | N/A | 86 | 86 |
| Discontinuations | |||
| Transformation | 9 | 3 | 12 |
| Loss of response | 11 | 0 | 11 |
| Lack of efficacy | 5 | 1 | 6 |
| Toxicity | |||
| Anemia | 2 | 0 | 2 |
| Other | 3 | 1 | 4 |
| Other | 3 | 3 | 6 |
| Death | 1 | 2 | 3 |
| Withdrawal of consent | 1 | 0 | 1 |
| Total | 35 | 10 | 45 |
| . | Ruxolitinib . | BAT . | Total . |
|---|---|---|---|
| Assigned therapy switches | |||
| Patients that switched BAT therapy at least once | N/A | 30 | 30 |
| Total number of times BAT therapy was switched | N/A | 86 | 86 |
| Discontinuations | |||
| Transformation | 9 | 3 | 12 |
| Loss of response | 11 | 0 | 11 |
| Lack of efficacy | 5 | 1 | 6 |
| Toxicity | |||
| Anemia | 2 | 0 | 2 |
| Other | 3 | 1 | 4 |
| Other | 3 | 3 | 6 |
| Death | 1 | 2 | 3 |
| Withdrawal of consent | 1 | 0 | 1 |
| Total | 35 | 10 | 45 |
N/A, not applicable.